Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Phio Pharmaceuticals Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
PHIO
Nasdaq
2834
https://phiopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Phio Pharmaceuticals Corp
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
- Apr 22nd, 2024 5:10 pm
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
- Apr 16th, 2024 11:30 am
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
- Apr 11th, 2024 11:30 am
National Spotlight Features Phio’s Innovative RNAi Technology Platform
- Apr 3rd, 2024 11:30 am
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
- Apr 2nd, 2024 11:30 am
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
- Mar 21st, 2024 11:30 am
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
- Mar 13th, 2024 6:00 pm
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
- Mar 6th, 2024 3:30 pm
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
- Jan 31st, 2024 1:00 pm
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
- Dec 7th, 2023 1:00 pm
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 9:30 pm
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
- Nov 9th, 2023 12:30 pm
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
- Nov 3rd, 2023 4:00 pm
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
- Oct 12th, 2023 3:10 pm
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Oct 12th, 2023 3:00 pm
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
- Oct 11th, 2023 11:30 am
Phio CEO to Speak at Wainwright Conference in New York in September
- Sep 6th, 2023 11:30 am
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
- Aug 21st, 2023 11:30 am
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 10th, 2023 8:30 pm
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
- Jun 2nd, 2023 5:30 pm
Scroll